Nemaura Medical to Present at Credit Suisse 2020 Virtual Diabetes Sessions
June 10 2020 - 7:00AM
Business Wire
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the
“Company”), a medical technology company focused on developing
micro-systems-based wearable diagnostic devices and currently
commercializing sugarBEAT®, its non-invasive and flexible
continuous glucose monitor (“CGM”), together with BEAT®diabetes, a
planned health subscription service designed to help people with
Type 2 diabetes and prediabetes through personalized lifestyle
coaching, today announced its CEO, Dr. Faz Chowdhury, will present
at the Credit Suisse 2020 Virtual Diabetes Sessions on Friday, June
12, 2020 at 10:15 a.m. ET.
The Virtual Diabetes Sessions include discussions with industry
experts and private and public companies developing technologies
and therapeutics for diabetes. The online event will take place on
June 12 and 15, in conjunction with this year’s American Diabetes
Association virtual meeting.
About Nemaura Medical, Inc.:
Nemaura Medical, Inc. (NMRD), is a medical technology company
commercializing BEAT®diabetes, a health subscription service
designed to help people with diabetes and prediabetes better manage
diabetes and reverse Type 2 diabetes or prevent diabetes through
1-on-1 lifestyle coaching and behavior driven by real time
continuous glucose monitoring (CGM) and daily glucose trend data
provided by sugarBEAT®, a non-invasive and flexible CGM.
For more information visit: www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura’s ongoing studies,
including the safety and efficacy of Nemaura’s sugarBEAT® system,
the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
sugarBEAT®, the availability of substantial additional equity or
debt capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
sugarBEAT®. These and other risks and uncertainties are identified
and described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200610005262/en/
Investor Contact: Dave Gentry, CEO RedChip Companies
Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498
dave@redchip.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024